Agency Header

Drug Utilization Review Board

The DUR Board is responsible for the establishment of standards and criteria for the prospective and retrospective DR programs.  The DR Board is charged with making recommendations for educational interventions to prescribers and pharmacists to identify and reduce overuse, abuse, fraud, and inappropriate or medically unnecessary care.  Xerox State Healthcare, LLC  assists the pharmacy program in conducting population-based educational interventions, approved by the DR Board, for both medical  prescribers and pharmacy providers.
Drugs or drug classes which are reviewed and found to be inappropriately utilized or have significant safety concerns are deemed candidates for prior authorization.  These reviews are considered by the DR Board and appropriate criteria for approval are determined by them, with input from medical and pharmacy providers, drug manufactures, and other experts.

Lester Labus, MD, Chairman                   Ernest Miller DO 
Kc Lovin, PA-C, Vice-Chair  Mary Nemeth Pyles, MSN, RN, CS
C.K. Babcock, PharmD  Patrick Regan, PharmD
Scott Brown, RPh  Christopher Terpening, PharmD, PhD
Myra Chiang, MD          John Vanin, MD 

Follow us on Facebook